Caretaker Medical, creator of the Caretaker4 wireless CNIBP Vital signs monitor for continuous non-invasive blood pressure (CNIBP) and vital signs monitoring, has received CE certification approval.

Infraredx Inc. announced the Makoto Intravascular Imaging System, and accompanying Dualpro intravascular ultrasound and near-infrared spectroscopy (IVUS+NIRS) catheter, is now available in Japan. The launch follows a successful Spring 2018 limited market release, which included more than 10 hospitals in Japan.

The Centers for Medicare & Medicaid Services (CMS) issued a proposed rule August 9 that would overhaul the Medicare Shared Savings Program established by the Affordable Care Act and launched in 2012. The Medicare Shared Savings Program is the umbrella under which the vast majority of Medicare’s Accountable Care Organizations (ACOs) operate. The redesigned program is called Pathways to Success.

Design of Medical Devices Conference

Medtronic plc announced the start of a pilot study of its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system, with the first patient implant performed at Christchurch Hospital in New Zealand. The implant represents the first intended long-term patient use of the device, which is similar in size to transvenous ICDs.

Acute Cardiac Unloading and Recovery (A-CURE) Symposium

dvancing the science and mechanistic understanding of acute cardiac unloading, supporting the translation of basic and clinical research into therapies aimed at heart muscle recovery.. For more information: https://www.youtube.com/watch?v=ZtqCMCWynsE

August 8, 2018 — The American Society of Nuclear Cardiology’s (ASNC) Annual Scientific Session, ASNC2018, will kick off with a full day of educational sessions on Sept. 6, and run through Sept. 9 in San Francisco.

Boston Scientific Corp. announced it has signed an agreement to acquire Veniti Inc., which has developed and commercialized the Vici Venous Stent System for treating venous obstructive disease. Boston Scientific has been an investor in Veniti since 2016 and currently owns 25 percent of the company. The transaction price for the remaining stake consists of $108 million up-front cash, as well as up to $52 million in payments contingent upon U.S. Food and Drug Administration (FDA) approval of the Vici stent system.

Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form preeclampsia further proves the condition mainly damages the heart’s ability to relax between contractions, making the organ overworked and poor at pumping blood.

Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the first-ever study demonstrating the benefits of patient-to-patient connectivity in the management of familial chylomicronemia syndrome (FCS). FCS is a rare, potentially life-threatening disease with multiple severe, daily and chronic manifestations that affect one’s ability to work and engage in activities of everyday living. Results from the CONNECT study, which surveyed both FCS patients and their caregivers, were published in July in Expert Opinion on Orphan Drugs.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now